呼吸道合胞病毒（RSV）感染是引發(fā)嬰幼兒細(xì)支氣管炎、肺炎的主要病因之一，會導(dǎo)致嚴(yán)重的呼吸系統(tǒng)疾病，會增加罹患哮喘的風(fēng)險(xiǎn)。帕利珠單抗和利巴韋林可用于預(yù)防和治療RSV感染，兩者均推薦用于RSV感染風(fēng)險(xiǎn)最高的患者，但其有益作用尚有爭議?？筊SV藥物的研究主要集中于不同的作用機(jī)制如抑制病毒融合、靶向非融合靶點(diǎn)和靶向病毒宿主的抑制劑。因此，預(yù)防或治療呼吸道合胞病毒感染，深入研究抗病毒策略，指導(dǎo)候選藥物篩選尤顯突出，但是至今仍沒有抗病毒藥物或疫苗被批準(zhǔn)用于RSV感染的治療或預(yù)防。隨著病毒學(xué)的深入研究，研究者將開發(fā)針對病毒靶點(diǎn)蛋白或宿主細(xì)胞因子的一系列的抗病毒藥物，這些藥物研發(fā)將為抗病毒提供新的途徑。

Respiratory syncytial virus (RSV) infection is one of the main causes of bronchiolitis and pneumonia in infants and young children. RSV causes severe respiratory diseases and increases the risk of asthma. Palizumab and ribavirin can be used to prevent and treat RSV infection, and both are recommended for patients with the highest risk of RSV infection, but their beneficial effects are controversial. Research on antiviral drugs has focused on different mechanisms of action, such as inhibiting viral fusion, targeting non-fused targets, and inhibitors targeting viral hosts. Therefore, prevention or treatment of respiratory syncytial virus infection, in-depth study of antiviral strategies, and guidance of drug candidate screening are particularly prominent. Although researchers have made great efforts to prevent this virus, no antiviral drugs or vaccines have been approved for the treatment or prevention of RSV infection. With the in-depth study of virology, researchers will develop a series of antiviral drugs targeting viral target proteins or host cytokines. The development of these drugs will provide new ways for antivirus.

R974